X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VVD-130037 is the investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, which is investigated for the treatment of advanced solid tumors.
Lead Product(s): VVD-130037
Therapeutic Area: Oncology Product Name: VVD-130037
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Vividion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Kerendia/Firialta (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block harmful effects of MR overactivation and expands clinical development program investigating finerenone for potential treatment of heart failure.
Lead Product(s): Finerenone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kerendia
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block harmful effects of MR overactivation, which is investigating for the treatment of heart failure.
Lead Product(s): Finerenone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kerendia
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CPC Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Under the agreement, Bayer will provide Nubeqa to Celcuity for its Phase 1b/2 trial of PKI-587 (gedatolisib), a potent inhibitor that selectively targets all Class I isoforms of PI3K and mTOR, in combination with darolutamide in metastatic castration resistant prostate cancer.
Lead Product(s): Gedatolisib,Darolutamide
Therapeutic Area: Oncology Product Name: PF-05212384
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Celcuity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 22, 2023
Details:
Eylea HD(aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor approved in 8mg dose for the treatment of neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea HD
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
AB-1003 (also known as LION-101) is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.
Lead Product(s): AB-1003
Therapeutic Area: Genetic Disease Product Name: AB-1003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.
Lead Product(s): Emodepside
Therapeutic Area: Infections and Infectious Diseases Product Name: BAY 44-4400
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Swiss TPH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2023
Details:
Under the terms of the agreement, NorthStar will provide Bayer with its environmentally preferred, non-carrier added Ac-225. NorthStar’s Ac-225 will be used by Bayer for several of its radiopharmaceutical programs, including Actinium-225 conjugated Therapies.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 18, 2023
Details:
Bayer and Peking University will advance research into drug discovery and development, while accelerating scientific research on cutting-edge technologies, with the focus on selected key areas of interests, such as oncology, cardiorenal, immunology and cell and gene therapy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Peking University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 10, 2023
Details:
The partnership aims for the development of multiple clinical candidates including, BAY401016, a mAb targeting the protein Semaphorin-3A, is being developed in phase I study as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.
Lead Product(s): BAY401016
Therapeutic Area: Genetic Disease Product Name: BAY401016
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Evotec
Deal Size: $351.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
